Darzalex Daratumumab Injection

1. Indications and Usage
Monotherapy:
Indicated for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, or who are double-refractory to a proteasome inhibitor and an immunomodulatory agent.
Combination Therapy:
Indicated in combination with:
Lenalidomide and Dexamethasone: For patients with previously untreated multiple myeloma (ineligible for autologous stem cell transplant) or previously treated multiple myeloma.
Bortezomib and Dexamethasone: For patients with previously untreated multiple myeloma.
Pomalidomide and Dexamethasone: For patients with previously treated multiple myeloma.
Isatuximab, Pomalidomide and Dexamethasone: For patients with previously treated multiple myeloma.
2. Dosage and Administration
Route of Administration:
Intravenous (IV) Infusion: For Darzalex (IV formulation).
Subcutaneous (SC) Injection: For Darzalex Faspro (SC formulation).
Recommended Dosage (IV Formulation):
Dose: 16 mg/kg body weight.
Schedule (Monotherapy/Combination):
Weeks 1–8: Once weekly.
Weeks 9–24: Every other week.
Week 25 onwards: Every 4 weeks.
Note: For the first infusion, the dose can be split over two consecutive days (8 mg/kg each day) to reduce infusion reactions.
Premedication:
Administer acetaminophen, an antihistamine, and a corticosteroid prior to each infusion to mitigate infusion-related reactions (IRR).
3. Mechanism of Action
CD38 Targeting:
Daratumumab binds to CD38, a type III transmembrane glycoprotein expressed on myeloma cells and various immune regulatory cells.
Cytotoxicity and Immunomodulation:
It induces tumor cell death through multiple mechanisms:
1. Immune Mediation: Antibody-Dependent Cellular Cytotoxicity (ADCC), Complement-Dependent Cytotoxicity (CDC), and Antibody-Dependent Cellular Phagocytosis (ADCP).
2. Direct Apoptosis: Binding to CD38 induces direct apoptosis.
3. Immunomodulation: Depletes CD38+ immunosuppressive regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), thereby enhancing T-cell and NK-cell responses.
4. Safety and Warnings
Infusion-Related Reactions (IRR):
Occur in a significant percentage of patients, primarily during the first infusion. Symptoms include nasal congestion, cough, throat irritation, and dyspnea. Close monitoring is required.
Interference with Laboratory Tests:
Daratumumab binds to the CD38 antigen on red blood cells, causing a positive direct antiglobulin test (DAT). It can also interfere with serum protein electrophoresis (SPEP) and immunofixation (IFE)assays, potentially complicating the assessment of treatment response.
Infections:
Increased risk of serious bacterial, fungal, and viral infections. Prophylactic antiviral therapy (e.g., acyclovir) is recommended.
Embryo-Fetal Toxicity:
Can cause fetal harm; pregnancy testing is recommended before initiation.
5. Adverse Reactions
Most Common (Incidence ≥20%):
Infusion-related reactions.
Fatigue.
Musculoskeletal pain.
Nausea, diarrhea, cough.
Asthenia.
Hematologic toxicities: Neutropenia, Thrombocytopenia, Anemia, Leukopenia.
6. Drug Interactions
Immunosuppressive Agents:
Concomitant use with other immunosuppressive therapies may increase the risk of infection.
Vaccines:
Avoid live virus vaccines during treatment.
7. Pharmaceutical Information
Chemical Composition:
Active Ingredient: Daratumumab.
Appearance: Clear, colorless to slightly yellowish liquid.
Storage: Store at 2°C–8°C. Do not freeze or shake.